Company intelligence / Profile preview

AtlasXomics

New Haven, Connecticut, United Statesatlasxomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

AtlasXomics has commercialized the DBiT-seq platform for high-resolution spatial multiomic profiling at single-cell resolution. Their assays enable mapping of chromatin accessibility and histone modifications across tissues. The technology has been adopted by over 50 laboratories worldwide and is being applied to diverse tissue types to study mechanisms underlying complex diseases. No clinical results apply as they do not develop therapeutics.

Therapeutic areas: OncologyImmunologyOtherCardiovascularNeurology
Modalities: Multi-omics (epigenomics, transcriptomics, proteomics)Spatial ATAC-seq (chromatin accessibility)Spatial CUT&Tag (histone modifications and chromatin proteins)
Industry: Non-Drug Biotech

Partnerships

EpiCypher (for proprietary reagents/antibodies in spatial CUT&Tag assays)

Beyond the preview

Go deeper on AtlasXomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtlasXomics.

Explore the full profile